FDA Announces Joint Meeting of Advisory Committees to Discuss New Asthma Treatment, AstraZeneca's Symbicort, and Pfizer's Xeljanz

Summary

The US Food and Drug Administration (FDA) has scheduled a joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and the Pediatric Advisory Committee to discuss new asthma treatments, including AstraZeneca's Symbicort and Pfizer's Xeljanz, and to review the safety and efficacy of these medications.